{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22849743",
  "DateCompleted": {
    "Year": "2012",
    "Month": "10",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.5858/arpa.2011-0424-OA"
    ],
    "Journal": {
      "ISSN": "1543-2165",
      "JournalIssue": {
        "Volume": "136",
        "Issue": "8",
        "PubDate": {
          "Year": "2012",
          "Month": "Aug"
        }
      },
      "Title": "Archives of pathology & laboratory medicine",
      "ISOAbbreviation": "Arch Pathol Lab Med"
    },
    "ArticleTitle": "Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.",
    "Pagination": {
      "StartPage": "935",
      "EndPage": "946",
      "MedlinePgn": "935-46"
    },
    "Abstract": {
      "AbstractText": [
        "Fusions of androgen-regulated genes and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) occur in approximately 50% of prostate cancers, encoding a truncated ERG product. In prostatectomy specimens, ERG rearrangements are greater than 99% specific for prostate cancer or high-grade prostatic intraepithelial neoplasia adjacent to ERG-rearranged prostate cancer by fluorescence in situ hybridization and immunohistochemistry.",
        "To evaluate ERG staining by immunohistochemistry on needle biopsies, including diagnostically challenging cases.",
        "Biopsies from a retrospective cohort (n \u200a=\u200a 111) enriched in cores requiring diagnostic immunohistochemistry and a prospective cohort from all cases during 3 months (n \u200a=\u200a 311) were stained with an anti-ERG antibody (clone EPR3864).",
        "Among evaluable cores (n \u200a=\u200a 418), ERG staining was confined to cancerous epithelium (71 of 160 cores; 44%), high-grade prostatic intraepithelial neoplasia (12 of 68 cores; 18%), and atypical foci (3 of 28 cores; 11%), with staining in only 2 of 162 cores (1%) diagnosed as benign. The ERG was expressed in about 5 morphologically benign glands across 418 cores and was uniformly expressed by all cancerous glands in 70 of 71 cores (99%).",
        "ERG staining is more prostate cancer-specific than \u03b1-methylacyl-coenzyme A racemase, and staining in an atypical focus supports a diagnosis of cancer if high-grade prostatic intraepithelial neoplasia can be excluded. Thus, ERG staining shows utility in diagnostically challenging biopsies and may be useful in molecularly subtyping prostate cancer and in stratifying isolated high-grade prostatic intraepithelial neoplasia by risk of subsequent cancer."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48104-5054, USA."
          }
        ],
        "LastName": "Tomlins",
        "ForeName": "Scott A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Palanisamy",
        "ForeName": "Nallasivam",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Siddiqui",
        "ForeName": "Javed",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Chinnaiyan",
        "ForeName": "Arul M",
        "Initials": "AM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kunju",
        "ForeName": "Lakshmi P",
        "Initials": "LP"
      }
    ],
    "GrantList": [
      {
        "GrantID": "P50 CA069568",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U01 CA111275",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U01 CA113913",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P50 CA69568",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Evaluation Study",
      "Journal Article",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Arch Pathol Lab Med",
    "NlmUniqueID": "7607091",
    "ISSNLinking": "0003-9985"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "ERG protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oncogene Proteins, Fusion"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Trans-Activators"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Transcriptional Regulator ERG"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibody Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Biopsy, Needle"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cohort Studies"
    },
    {
      "QualifierName": [
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Epithelium"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Rearrangement"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunohistochemistry"
    },
    {
      "QualifierName": [],
      "DescriptorName": "In Situ Hybridization, Fluorescence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Grading"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Oncogene Proteins, Fusion"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Prostate"
    },
    {
      "QualifierName": [
        "diagnosis",
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Prostatic Intraepithelial Neoplasia"
    },
    {
      "QualifierName": [
        "diagnosis",
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Prostatic Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sensitivity and Specificity"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Trans-Activators"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transcriptional Regulator ERG"
    }
  ]
}